文献速递胰腺与胆道疾病消化道肿瘤与早癌

CA19-9作为胰腺癌早期检测锚定标志物的提前期轨迹

Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
PubMed 文献 · Gastroenterology · 2020-12-14

该研究基于PLCO队列175例胰腺癌患者诊断前5年内的血清及875例匹配对照,发现CA19-9在诊断前2年开始指数性升高,诊断前0-6个月以99%特异性检测所有病例的敏感性达60%,早期病例达50%。联合LRG1和TIMP1可提高CA19-9低于截断值者的敏感性13.2%。

要点

  • CA19-9在胰腺癌诊断前2年开始指数升高。
  • 诊断前0-6个月,99%特异性下敏感性60%(所有病例)或50%(早期病例)。
  • CA19-9联合LRG1和TIMP1可提升早期检测敏感性。

核心结论

  • CA19-9可作为胰腺癌早期检测的锚定标志物。

研究设计与样本

  • 病例对照研究,使用PLCO试验中175例胰腺癌患者诊断前5年内采集的血清及875例匹配对照。
  • 另独立检测129例可切除胰腺癌诊断时血清及275例对照(100健康、50慢性胰腺炎、125非癌性胰腺囊肿)。

主要发现

  • PLCO队列中CA19-9从诊断前2年开始指数升高,诊断前0-6个月99%特异性下敏感性60%(所有病例)、50%(早期病例)。
  • 区分新诊断可切除胰腺癌与健康对照的敏感性为64%(99%特异性)。
  • 区分可切除胰腺癌与慢性胰腺炎的敏感性为46%(99%特异性),与非癌性囊肿为30%(99%特异性)。

临床怎么用

  • CA19-9可作为胰腺癌高危人群早期检测的锚定标志物,联合LRG1和TIMP1可能提升CA19-9阴性者的检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is substantial interest in liquid biopsy approaches for cancer early detection among subjects at risk, using multi-marker panels. CA19-9 is an established circulating biomarker for pancreatic cancer; however, its relevance for pancreatic cancer early detection or for monitoring subjects at risk has not been established. METHODS: CA19-9 levels were assessed in blinded sera from 175 subjects collected up to 5 years before diagnosis of pancreatic cancer and from 875 matched controls from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. For comparison of performance, CA19-9 was assayed in blinded independent sets of samples collected at diagnosis from 129 subjects with resectable pancreatic cancer and 275 controls (100 healthy subjects; 50 with chronic pancreatitis; and 125 with noncancerous pancreatic cysts). The complementary value of 2 additional protein markers, TIMP1 and LRG1, was determined. RESULTS: In the PLCO cohort, levels of CA19-9 increased exponentially starting at 2 years before diagnosis with sensitivities reaching 60% at 99% specificity within 0 to 6 months before diagnosis for all cases and 50% at 99% specificity for cases diagnosed with early-stage disease. Performance was comparable for distinguishing newly diagnosed cases with resectable pancreatic cancer from healthy controls (64% sensitivity at 99% specificity). Comparison of resectable pancreatic cancer cases to subjects with chronic pancreatitis yielded 46% sensitivity at 99% specificity and for subjects with noncancerous cysts, 30% sensitivity at 99% specificity. For prediagnostic cases below cutoff value for CA19-9, the combination with LRG1 and TIMP1 yielded an increment of 13.2% in sensitivity at 99% specificity (P = .031) in identifying cases diagnosed within 1 year of blood collection. CONCLUSION: CA19-9 can serve as an anchor marker for pancreatic cancer early detection applications.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Fahrmann JF, Schmidt CM, Mao X, et al. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2020. PMID: 33333055. doi:10.1053/j.gastro.2020.11.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。